Does Gateway Health Plan Cover Viagra?

What Is Gateway Health Plan and Who Does It Cover?

Gateway Health Plan is a managed-care organization operating primarily Medicaid, Medicare Advantage, and CHIP plans across Pennsylvania and other states. The plan contracts with state Medicaid agencies, which means coverage rules follow both federal Medicaid statute and state-specific amendments.

Medicaid Managed Care vs. Commercial Insurance

Medicaid managed-care plans like Gateway operate under Section 1932 of the Social Security Act. Federal law gives states broad authority to exclude drugs used to treat sexual or erectile dysfunction from Medicaid formularies. Pennsylvania's Medicaid drug program, for example, lists erectile dysfunction agents as a non-covered category under its preferred drug list (PDL) unless a separate clinical exception applies.

Commercial Gateway plans (sold through employer groups or the ACA marketplace) follow different rules and may include ED drugs at a higher cost-sharing tier. Checking the specific plan's Summary of Benefits and Coverage document is the only way to confirm your tier.

Finding Your Specific Gateway Formulary

Gateway Health publishes its drug formularies online at the Pennsylvania Department of Human Services drug program page. Formularies are updated quarterly. A drug absent from the formulary in January may appear by April if the state PDL committee adds it. Call the member services number on your insurance card (typically 1-800-392-1147 for Gateway Health Pennsylvania Medicaid) and ask specifically: "Is sildenafil citrate covered for erectile dysfunction on my plan?"

Does Federal Law Allow Medicaid to Exclude Viagra?

Yes. Under 42 U.S.C. § 1396r-8(d)(2), states may exclude or restrict coverage of drugs used to promote fertility, cosmetic purposes, or sexual dysfunction without violating the Medicaid drug rebate statute. The Centers for Medicare and Medicaid Services confirm this exclusion authority in their Medicaid Drug Rebate Program guidance.

The 2003 Federal Rule That Started the Exclusion

A 2003 CMS State Medicaid Director letter clarified that ED drugs, including sildenafil, do not need to be covered under Medicaid. Within two years, more than 40 states adopted explicit formulary exclusions. Pennsylvania adopted its exclusion shortly after, and Gateway Health's Medicaid plans reflect that state decision.

Medicare Part D and Viagra

Medicare Part D plans face a similar statutory exclusion under 42 U.S.C. § 1395w-102(e)(2)(A), which prohibits Part D coverage of drugs used for the treatment of sexual or erectile dysfunction. Gateway Medicare Advantage plans therefore cannot cover Viagra or sildenafil for ED under the Part D benefit, regardless of plan design. The FDA's drug labeling for sildenafil citrate (NDA 020895) confirms the primary approved indication remains erectile dysfunction, which triggers the exclusion.

When Is Sildenafil Covered by Gateway Health Plan?

Sildenafil has a second FDA-approved indication: pulmonary arterial hypertension (PAH), marketed as Revatio at 20 mg three times daily. That indication is not subject to the ED drug exclusion, and Gateway Medicaid plans typically do cover Revatio or generic sildenafil 20 mg for PAH with prior authorization.

Pulmonary Arterial Hypertension Coverage

The FDA approved sildenafil (Revatio) for PAH in June 2005 (NDA 021845). Clinical evidence supporting this indication includes the SUPER-1 trial (N=278), which showed sildenafil 20 mg three times daily improved 6-minute walk distance by a mean of 45 meters vs. Placebo at 12 weeks (P<0.001). The SUPER-1 results were published in the New England Journal of Medicine.

Gateway Health plans generally place sildenafil 20 mg for PAH on a specialty tier requiring prior authorization and documentation of a confirmed PAH diagnosis by right-heart catheterization.

Raynaud's Phenomenon and Off-Label Uses

Some physicians prescribe sildenafil off-label for secondary Raynaud's phenomenon. A Cochrane systematic review found phosphodiesterase-5 inhibitors reduced frequency of Raynaud's attacks by approximately 35% compared with placebo. The Cochrane review is available here. Off-label prescribing does not guarantee coverage; Gateway would still require a prior authorization citing medical necessity documentation for any non-PAH sildenafil claim.

How Does Prior Authorization Work for Sildenafil Under Gateway?

Prior authorization (PA) is a formal process where your prescriber submits clinical documentation to Gateway before the pharmacy will dispense the drug at a covered rate. For sildenafil, PA is almost always required even when coverage exists.

Step 1: Prescriber Submits PA Request

Your physician completes a PA form specific to Gateway Health. For PAH indications, the form typically asks for:

• Confirmed PAH diagnosis code (ICD-10: I27.0)
• Results of right-heart catheterization showing mean pulmonary artery pressure >20 mmHg
• Documentation that first-line therapies (e.g., ambrisentan, bosentan) were considered or tried
• Prescriber NPI and DEA numbers

Step 2: Gateway Reviews Within Regulatory Timeframes

Federal Medicaid managed-care regulations at 42 C.F.R. § 438.210 require expedited authorization decisions within 72 hours for urgent requests and standard decisions within 14 calendar days. Gateway Health is contractually bound to these timelines under its Pennsylvania PAHP agreement.

Step 3: Approval, Denial, or Request for Additional Information

If approved, the authorization typically covers a 30- or 90-day supply. If denied, the denial letter must state the specific clinical reason and include information on how to appeal. CMS guidance on managed-care appeals rights is published at HealthCare.gov.

What Are Your Options If Gateway Denies Viagra Coverage?

A denial is not a final answer. You have at least three formal recourse paths.

Internal Appeal

File a written internal appeal within the deadline stated on your denial letter (often 60 days for Medicaid plans). Your prescriber should submit a letter of medical necessity that cites peer-reviewed evidence. For ED specifically, the American Urological Association's 2018 Guideline on Erectile Dysfunction states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for ED in the absence of contraindications (Strong Recommendation; Evidence Level Grade A)." Quoting that language directly in your appeal letter signals clinical credibility.

State Fair Hearing

If the internal appeal fails, Medicaid enrollees have the right to a state fair hearing under 42 C.F.R. § 431.200. Pennsylvania's Office of Long-Term Living administers these hearings. You must request a hearing within 90 days of the final internal appeal denial.

External Review

Commercial Gateway plan members (non-Medicaid) have access to independent external review under the ACA. An independent review organization makes a binding decision within 45 days for standard reviews or 72 hours for expedited urgent-care reviews. The Pennsylvania Insurance Department oversees external review requests.

How Much Does Sildenafil Cost Without Gateway Coverage?

Generic sildenafil has become one of the most price-competitive drugs in American retail pharmacy since Teva's generic launch in December 2017. You do not need Gateway coverage to afford it.

Retail Cash Prices

At major chains, 6 tablets of sildenafil 100 mg typically cost $10, $30 with a GoodRx or similar discount card. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists sildenafil 100 mg at roughly $0.28 per tablet plus dispensing fees, making a 30-tablet supply under $15. These prices are often lower than the copay on a covered generic tier.

Manufacturer Patient Assistance

Pfizer no longer offers meaningful direct assistance for Viagra since generic competition collapsed the branded market share to under 2% of all sildenafil prescriptions. Generic manufacturers do not typically run patient assistance programs. Telehealth platforms affiliated with compounding pharmacies sometimes offer sildenafil at $1, $3 per dose with a provider consultation fee.

Clinical Context: Erectile Dysfunction Prevalence and Treatment Evidence

Erectile dysfunction affects an estimated 30 million men in the United States, according to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) data. Prevalence rises sharply with age: approximately 40% of men at age 40 and 70% by age 70 experience some degree of ED, based on the Massachusetts Male Aging Study published in the Journal of Urology.

Phosphodiesterase-5 Inhibitor Efficacy

Sildenafil's key Phase III trial program, reviewed in the original NEJM publication (Goldstein et al., 1998, N=532), showed 69% of attempts at sexual intercourse were successful in the sildenafil group vs. 22% in the placebo group (P<0.001). The drug works by inhibiting PDE5, increasing cyclic GMP, and relaxing smooth muscle in the corpus cavernosum. Onset is typically 30 to 60 minutes; duration is 4 to 6 hours.

Comparing PDE5 Inhibitors

Tadalafil (Cialis, generic available since 2018) offers a longer half-life of approximately 17.5 hours and is approved for once-daily dosing at 2.5 or 5 mg. A meta-analysis of 82 randomized controlled trials (N=18,605) published in the European Urology journal found all approved PDE5 inhibitors produced statistically equivalent improvements in International Index of Erectile Function (IIEF) scores, with no single agent demonstrating superiority for efficacy. Tadalafil generic is sometimes preferred by insurers when covered, due to lower wholesale acquisition cost per daily-use dose.

Cardiovascular Safety Considerations

The Princeton Consensus (Third Princeton Consensus Conference, 2012) stratified men with cardiovascular disease into low-, intermediate-, and high-risk categories for sexual activity and PDE5 inhibitor use. Men on nitrate therapy of any kind should not take sildenafil due to risk of severe hypotension. Gateway Health's PA criteria typically include a cardiovascular safety checklist aligned with these consensus recommendations.

Alternatives to Viagra That Gateway May Cover

If sildenafil for ED remains non-covered, several alternatives may appear on Gateway's formulary or cost significantly less out of pocket.

Generic Tadalafil

Generic tadalafil (formerly Cialis) became available in October 2018. Some commercial Gateway plans place generic tadalafil on a Tier 2 preferred generic formulary position, particularly when prescribed for benign prostatic hyperplasia (BPH, ICD-10: N40.1), where tadalafil 5 mg daily is FDA-approved. FDA approval for tadalafil in BPH is documented in NDA 021368. If a patient has both ED and BPH, a single tadalafil 5 mg daily prescription for BPH may also address ED, and that BPH indication may qualify for coverage.

Vacuum Erection Devices

Durable medical equipment (DME) claims for vacuum erection devices fall under a different benefit category. Gateway Medicaid plans occasionally cover these under DME benefits with a physician order, although coverage varies by plan year. HCPCS code L7900 applies to vacuum erection devices for Medicaid DME billing.

Intracavernosal Injection Therapy

Alprostadil (Caverject, Edex), delivered via penile injection, is FDA-approved for ED and carries a different formulary status than oral PDE5 inhibitors. Some Gateway plans place alprostadil on a covered specialty tier because it is not classified as an "oral ED agent" under standard Medicaid exclusion language. FDA prescribing information for alprostadil injection (NDA 020488) is available on the FDA site.

Penile Prosthesis Surgery

For men with refractory ED, implantable penile prostheses (inflatable or malleable) are covered under Gateway's surgical benefits when medical necessity criteria are met. The AUA guideline notes that satisfaction rates for inflatable penile prostheses exceed 90% in properly selected patients. This option requires urology specialty referral and precertification.

Testosterone Deficiency and ED: A Frequently Missed Connection

Approximately 20 to 25% of men presenting with ED have concurrent hypogonadism (testosterone deficiency), according to data reviewed in the Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism. When testosterone levels are low (total testosterone <300 ng/dL by most laboratory reference ranges), PDE5 inhibitors are less effective.

Restoring testosterone to mid-normal range (400 to 700 ng/dL) before or alongside sildenafil therapy improves IIEF scores beyond what either therapy achieves alone. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (Rosenthal et al., N=140) showed combination testosterone plus sildenafil produced a mean IIEF-EF domain score improvement of 8.2 points vs. 5.6 points for sildenafil alone (P<0.05). Gateway Health may cover testosterone replacement therapy (injectable testosterone cypionate, topical gels) for documented hypogonadism under standard pharmacy benefits, separate from any ED drug exclusion.

The Endocrine Society guideline states: "We suggest prescribing testosterone therapy to men with symptomatic androgen deficiency who have low testosterone levels documented on at least two morning measurements." Checking serum testosterone before prescribing a PDE5 inhibitor for ED is therefore good clinical practice and may open a covered treatment pathway.

How to Talk to Your Doctor About Gateway Coverage

A structured conversation with your prescriber takes less than five minutes and can prevent weeks of pharmacy delays.

Ask These Specific Questions

1. "Is my prescription written for the FDA-approved indication that qualifies for Gateway coverage, or for ED specifically?"
2. "Do I have any comorbidities (BPH, PAH, Raynaud's) that might support a covered indication?"
3. "Can you check my testosterone level to rule out hypogonadism before we proceed?"
4. "If the claim is denied, will your office submit a PA and appeal on my behalf?"

What to Bring to the Appointment

Bring your Gateway Health member ID card, a list of current medications (nitrate use is a contraindication), and any prior lab work. If you have a cardiovascular history, bring your most recent ECG or cardiologist note. The American Heart Association's 2018 Scientific Statement on sexual activity and cardiovascular disease provides your cardiologist with the risk-stratification framework needed to clear you for PDE5 inhibitor use.

State-Specific Notes for Gateway Health Members

Gateway operates across multiple states with different Medicaid managed-care contracts. Rules differ.

Pennsylvania

Pennsylvania's Medicaid program (MA) explicitly excludes drugs for sexual dysfunction from the PDL under Pennsylvania Code Title 55, Chapter 1121. Gateway Health PA Medicaid members cannot receive covered sildenafil for ED under standard benefits. Pennsylvania's Department of Human Services pharmacy program information publishes the current PDL online.

West Virginia

Gateway Health also serves West Virginia Medicaid members. West Virginia follows a similar federal exclusion framework. Generic sildenafil for PAH remains accessible with PA.

Checking Your State's Current Rules

Medicaid policy changes annually during budget cycles. The Medicaid.gov Prescription Drug coverage page tracks state-by-state coverage policies. Use it to verify whether your state has adopted any recent amendments before filing a PA or appeal.